


Hepatic Abscess – Microbiology Summary Clinical Guideline

Reference number: CG-MICRO/2019/002



Empiric, intravenous antibiotics: no clinical concerns regarding sepsis

First line	Piperacillin tazobactam 4.5 g 8 hourly
Second line, if non-immediate without	Ceftriaxone 2 g 24 hourly and
systemic involvement penicillin allergy	Metronidazole 500 mg 8 hourly
Third line, if immediate rapidly evolving or	Ciprofloxacin 400 mg 12 hourly and
non-immediate with systemic involvement	Metronidazole 500 mg 8 hourly
penicillin allergy	

Empiric, intravenous antibiotics: clinical concerns regarding sepsis (life threatening organ dysfunction caused by a dysregulated host immune response to infection) secondary to hepatic abscess

First line	Piperacillin tazobactam 4.5 g 6 hourly ± If there are clinical concerns regarding the risk of methicillin resistant <i>Staphylococcus aureus</i> (MRSA), vancomycin or teicoplanin, <u>dose as</u> <u>per hospital guidelines</u> , vancomycin target pre dose level 15-20 mg/l, teicoplanin target pre dose level 15-30 mg/l
Second line, <u>if non-immediate</u> <u>without systemic involvement</u> <u>penicillin allergy</u>	Ceftazidime 2 g 8 hourly and Vancomycin or teicoplanin, <u>dose as per</u> <u>hospital guidelines</u> , vancomycin target pre dose level 15-20 mg/l, teicoplanin target pre dose level 15-30 mg/l and Metronidazole 500 mg 8 hourly
Third line, <u>if immediate rapidly</u> <u>evolving or non-immediate with</u> <u>systemic involvement penicillin</u> <u>allergy</u>	<u>Ciprofloxacin</u> 400 mg 8 hourly and Vancomycin or teicoplanin, <u>dose as per</u> <u>hospital guidelines</u> , vancomycin target pre dose level 15-20 mg/l, teicoplanin target pre dose level 15-30 mg/l and Metronidazole 500 mg 8 hourly



References

Bennett, J. E., Dolin, R., and Blaser, M. J. 2015. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 8th Edition. Elsevier. **Davis, J. and McDonald, M.** 2022. Pyogenic liver abscess. UpToDate. Available at: https://www.uptodate.com/contents/pyogenic-liver-abscess.

Johns Hopkins ABX Guide. 2019. Hepatic Abscess. Available at: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540259/al //Hepatic_Abscess.

Mavilla, M. G., Molina, M., and Wu, G. Y. 2016. The Evolving Nature of Hepatic Abscess: A Review. Journal of Clinical and Translational Hepatology.

Sanford Guide Antimicrobial Therapy. 2019. Hepatic Abscess. Available at: <u>https://www.sanfordguide.com/products/digital-subscriptions/</u>.

Seas, C. 2015. Hepatic abscess. DynaMed Plus. Available at: <u>http://www.dynamed.com/</u>.

Document control

Development of guidelines:	Kayleigh Lehal, Dr Peter Slovak, Dr Peter Thurley
Consultation with:	Lead Antimicrobial Pharmacist, Microbiology Consultant, Radiology Consultant
Version:	2
Approval date:	Antimicrobial Stewardship Group - 28/02/2023 Medicine Divisional Governance - 24/02/2023
Changes from previous version:	Introduction: reworded (minor) and reformatted (minor). Differential diagnosis. Investigation: reworded (minor) and reformatted (minor). Treatment: reworded (minor) and reformatted (minor). Management: reworded (minor) and reformatted (major). References: updated (minor).
Date uploaded:	29/03/2023
Next review date:	March 2026
Key contacts:	Dr Peter Slovak, Microbiology Consultant <u>p.slovak@nhs.net</u> Kayleigh Lehal, Lead Antimicrobial Pharmacist <u>kayleigh.lehal@nhs.net</u>